
Rein Therapeutics fell 54.7% from $1.22 to $0.55, behind the S&P 500's +13.3%. Its worst day was May 1 (−24.0%), and its low came Oct 19 at $0.55.
Story events cover the past 12 months · Times ET
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.11 beat the $-0.23 estimate on $0.00 revenue.
−1.6% · S&P 500 −1.7%
Rein Therapeutics shares rose 14.9%, while the S&P 500 rose 0.5%.
+14.9% · S&P 500 +0.5%
Rein Therapeutics closed at its highest level of the year, 54.1% above where the year started.
+0.5% · S&P 500 +1.0%
Rein Therapeutics shares fell 24.0%, while the S&P 500 rose 0.3%.
−24.0%, the year's worst day, on 12M shares, the year's heaviest volume · S&P 500 +0.3%
EPS of $-0.19 beat the $-0.49 estimate on $0.00 revenue.
−7.1% · S&P 500 −1.2%
EPS of $-0.10 beat the $-0.19 estimate on $0.00 revenue.
+2.3% · S&P 500 −0.2%
Rein Therapeutics closed at its lowest level of the year, 54.8% below where the year started.
−6.5% · S&P 500 +0.4%
Rein Therapeutics shares rose 20.7%, while the S&P 500 rose 0.6%.
+20.7%, the year's best day · S&P 500 +0.6%
Where it ended: a close of $0.55 on Nov 13, 2026. Up next: Q3 2026 earnings on Nov 16, 2026 (EPS est. $-0.10).
Nothing in the past 12 months.
All RNTX dividend history